GI Innovation Registers European Patent for Allergy Treatment and Microbiome Combination Therapy

GI Innovation announced on the 27th that a patent for the allergy treatment 'GI-301 (YH35324)' and microbiome combination therapy has been granted in Europe.

GI Innovation Logo [Photo by GI Innovation]

The granted patent covers an IgE inhibitor (IgE TRAP) without sequence limitations, and the microbiome is also registered without restrictions on its type, securing a broad scope of rights. This means that competitors can be fundamentally blocked from commercializing microbiomes combined with IgE TRAP through the patent, which is expected to be advantageous for commercialization.

According to MarketsandMarkets, Europe is a key market accounting for about 20% of the global probiotics market. The company also emphasized the significance of securing this patent right, noting that most major global probiotics companies such as Nestl? (Switzerland), Danone (France), and Probi (Sweden) are European companies.

Byung-geon Lee, Chairman of GI Innovation, stated, “Through the combination of GI-301 and probiotics, it is possible to expand indications not only for atopic diseases but also for food allergies, which currently lack adequate treatment options. The registration of this European patent is not only an important factor that can increase the value of GI-301 in licensing negotiations with global pharmaceutical companies but also a foothold for entering the European market, which holds a high share in the allergy market, making it highly meaningful.”

This content was produced with the assistance of AI translation services.